US09609G1004 - Common Stock
BLUEBIRD BIO INC
NASDAQ:BLUE (5/3/2024, 7:00:01 PM)
After market: 0.9199 +0.02 (+2.23%)0.8998
0 (-0.39%)
bluebird bio, Inc. is a clinical-stage biotechnology company, which engages in researching, developing and commercializing potentially transformative gene therapies for severe genetic diseases. The company is headquartered in Somerville, Massachusetts and currently employs 323 full-time employees. The company went IPO on 2013-06-19. The firm is focused on researching, developing, and commercializing potentially curative gene therapies for severe genetic diseases based on its lentiviral vector (LVV) gene addition platform. Its lead gene therapy programs for sickle cell disease, B-thalassemia, and cerebral adrenoleukodystrophy and is advancing research to apply new technologies to these and other diseases. The company has two gene therapies: ZYNTEGLO (betibeglogene autotemcel) and SKYSONA (elivaldogene autotemcel). ZYNTEGLO is the first gene therapy for people with B-thalassemia who require regular red blood cell transfusions. SKYSONA (elivaldogene autotemcel), also known as eli-cel, is used to slow the progression of eurologic dysfunction in boys 4-17 years of age with early, active cerebral adrenoleukodystrophy (CALD). The company is also developing (lovotibeglogene autotemcel), also known as lovo-cel, as a one-time treatment for patients with sickle cell disease (SCD).
BLUEBIRD BIO INC
455 Grand Union Boulevard
Somerville MASSACHUSETTS 02142
P: 13394999300
CEO: Nick Leschly
Employees: 323
Website: https://www.bluebirdbio.com/
WHY: NEW YORK, NY - (NewMediaWire) - May 03, 2024 - Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of bluebird bio, Inc. (NASDAQ: BLUE) between April 24, 2023 and December 8, 2023, both dates inclusive (the “Class Period”), of the important May 28, 2024 lead plaintiff deadline.
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
/PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against bluebird bio, Inc. ("Blue" or the...
/PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of bluebird bio, Inc. (NASDAQ: BLUE). Shareholders who purchased shares of BLUE...
/PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against bluebird bio, Inc....
Here you can normally see the latest stock twits on BLUE, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: